Replies to post #49277 on $heff's $tation of $tocks & $olid DD

[pmony5]

ZGNX completed offering at $2.00 share & Oppenhiemer stated their drug Mkt is closer to 500 Million Dollars.

Oppenhiemer Analyst note before Positive phase 3 results... Zogenix: Positive top-line Zohydro phase III results by end of August - Oppenheimer (4.07 )
Oppenheimer anticipates positive top-line Phase III results from ZGNX's Zohydro by the end of August, potentially driving the shares to the ~$5-6 range. As a reminder, Zohydro is ZGNX's novel, oral, single-entity controlled-release formulation of hydrocodone, intended to treat moderate to severe chronic pain. Our positive bias on Phase III results is based on strong phase II data, as well as the well-understood safety/efficacy profile of the hydrocodone class. If approved, they estimate Zohydro's relative advantages in safety and dosing convenience could help garner a meaningful portion of the branded hydrocodone market, resulting in peak sales of ~$500 mln. On positive data, they anticipate ZGNX to file an NDA in 2012, followed by an acceleration in partnership discussions later in 2012.